GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study to Evaluate rhuFab V2 in Subjects With Minimally Classic or Occult Subfoveal Neovascular Macular Degeneration
Phase 3
Completed
- Conditions
- First Posted Date
- 2003-03-26
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 720
- Registration Number
- NCT00056836
Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer
Phase 1
Completed
- Conditions
- First Posted Date
- 2002-10-18
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT00047762
- Locations
- 🇺🇸
Johns Hopkins Oncology Center, Baltimore, Maryland, United States
🇺🇸Indiana University Cancer Pavilion, Indianapolis, Indiana, United States
🇺🇸Mary Crowley Medical Research Center, Dallas, Texas, United States
A Study With Tarceva and Chemotherapy vs. Chemotherapy Alone in Patients With Advanced Lung Cancer
Phase 3
Completed
- Conditions
- First Posted Date
- 2002-10-17
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT00047736
- Locations
- 🇺🇸
Multinational Sites, Denver, Colorado, United States
🇺🇸Trial Information Center, Denver, Colorado, United States
Safety Study of rhuMAb 2C4 to Treat Advanced Solid Tumors
Phase 1
Completed
- Conditions
- First Posted Date
- 2001-11-16
- Last Posted Date
- 2015-07-27
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT00027027
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients With HIV-Associated Immune Thrombocytopenic Purpura
Phase 1
Completed
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT00002250
- Locations
- 🇺🇸
San Francisco Gen Hosp, San Francisco, California, United States
A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 (rCD4) in Patients With AIDS and AIDS-Related Complex
Phase 1
Completed
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT00002004
- Locations
- 🇺🇸
Genentech Inc, South San Francisco, California, United States
A Phase I Study of Recombinant CD4(rCD4) in Patients With AIDS and AIDS-Related Complex
Not Applicable
Completed
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT00002005
- Locations
- 🇺🇸
Genentech Inc, South San Francisco, California, United States
A Phase I Study of the Safety and Immunogenicity of Rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers
Phase 1
Completed
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT00001992
- Locations
- 🇺🇸
Walter Reed Army Institute of Research, Rockville, Maryland, United States
© Copyright 2024. All Rights Reserved by MedPath